Xlife Sciences AG Reports Success in Liver Diagnostics - x-nuclear
diagnostics GmbH Achieves Market Readiness

Xlife Sciences AG / Key word(s): Market launch/Product Launch
Xlife Sciences AG Reports Success in Liver Diagnostics - x-nuclear
diagnostics GmbH Achieves Market Readiness

26.06.2024 / 07:00 CET/CEST

---------------------------------------------------------------------------

Zurich, 26th of June 2024: Xlife Sciences AG announces significant progress
in the development and application of innovative diagnostic solutions. The
project company x-nuclear diagnostics GmbH, a 100% subsidiary of Xlife
Sciences AG, has achieved remarkable success in the research and application
of the new PET tracer DAZAmed.

A PET tracer is a special substance used in positron emission tomography
(PET) to visualize organ functions in the body. These tracers are
radioactive molecules that bind to specific structures in the body and emit
radiation, allowing detailed images of organs and their functions to be
created.

The PET tracer DAZAmed is the first of its kind developed specifically for
visualizing liver function. Initial applications have already successfully
diagnosed patients, underscoring the efficacy and reliability of this
innovative diagnostic tool. Additionally, a successful toxicity study in
animals and trials in patients have confirmed the safety, tolerability, and
efficacy of the tracer.

Another significant advancement is the GMP-compliant production of the
precursors of DAZAmed (excluding the radioactive ligand) by inflamed pharma
GmbH, a 70% subsidiary of Xlife Sciences AG, which meets production
standards and quality requirements, thus paving the way for clinical
commercialization. This further highlights the enormous synergy potential of
Xlife Sciences AG's highly diversified project portfolio.

The rollout of the DAZAmed PET tracer is planned for the third quarter of
2024, with initial revenues expected in Germany. The DAZAmed PET tracer will
be used in liver diagnostics for patients, representing an important
milestone in medical imaging and diagnostics.

Oliver R. Baumann, CEO of Xlife Sciences AG, comments on this progress: «We
at Xlife Sciences AG are proud to have reached another significant milestone
in medical diagnostics. The development and successful application of the
liver-specific PET tracer DAZAmed by our subsidiary x-nuclear diagnostics
GmbH is further proof of the innovative strength and commitment of our team.»

With these developments, Xlife Sciences AG continues its mission to advance
innovative and future-oriented technologies in healthcare and improve access
to advanced diagnostic solutions.

Financial calendar

     Annual Shareholders Meeting 2024    28 June 2024
     Half-Year Report 2024               19 September 2024

Xlife Sciences AG,
Talacker 35,
8001 Zurich,
Switzerland,
Phone +41 44 385 84 60
info@xlifesciences.ch, www.xlifesciences.ch,
Commercial Register Zurich CHE-330.279.788
Stock Exchange: SIX Swiss Exchange

Contact
Information for investors and journalists: Xlife Sciences AG, Dr. Dennis
Fink, dennis.fink@xlifesciences.ch

About Xlife Sciences AG (SIX: XLS)

Xlife Sciences is a Swiss company focused as incubator and accelerator on
the value development and commercialization of promising research projects
from universities and other research institutions in the life sciences
sector, with the aim of providing solutions for high unmet medical needs and
a better quality of life. The goal is to bridge research and development to
healthcare markets. Xlife Sciences takes carefully selected projects in the
four areas of technological platforms, biotechnology/ therapies, medical
technology, and artificial intelligence/digital health to the next stage of
development, and participates in their subsequent performance. For more
information, visit www.xlifesciences.ch

Disclaimer

Some of the information contained in this media release contains
forward-looking statements. Readers are cautioned that any such
forward-looking statements are not guarantees of future performance and
involve risks and uncertainties, and that actual results may differ
materially from those in the forward-looking statements as a result of
various factors. Xlife Sciences undertakes no obligation to publicly update
or revise any forward-looking statements.


---------------------------------------------------------------------------

End of Media Release

---------------------------------------------------------------------------

   Language:       English
   Company:        Xlife Sciences AG
                   Talacker 35
                   8001 Zürich
                   Switzerland
   Phone:          +41 44 385 84 60
   E-mail:         info@xlifesciences.ch
   Internet:       www.xlifesciences.ch
   ISIN:           CH0461929603
   Valor:          A2PK6Z
   Listed:         SIX Swiss Exchange
   EQS News ID:    1933059

End of News EQS News Service
---------------------------------------------------------------------------

1933059 26.06.2024 CET/CEST